Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | LTA4H | P09960 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3636153 | 0.84 | KDM4E (0.39) | POLBESR2CA2LTA4HALDH1A1 | |
| SCHEMBL3763119 | 0.73 | CA2 (0.45) | POLBESR2CA2ALDH1A1HPGD | |
| SCHEMBL3639080 | 0.73 | NISCH (0.35) | POLBESR2CA2NISCH | |
| SCHEMBL7777038 | 0.70 | CA2 (0.31) | CA2 | |
| SCHEMBL7777036 | 0.70 | CA2 (0.31) | CA2 | |
| SCHEMBL5010302 | 0.69 | CA2 (0.41) | CA2ALDH1A1KDM4EHPGDHTT | |
| SCHEMBL7765718 | 0.69 | CA2 (0.32) | CA2NISCH | |
| SCHEMBL7765721 | 0.69 | HRH3 (0.34) | CA2ALDH1A1NISCHTSHR | |
| SCHEMBL5804269 | 0.69 | NISCH (0.35) | CA2NISCHKMT2AMEN1 | |
| SCHEMBL5804265 | 0.69 | CA2 (0.32) | CA2NISCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214812-A1 | COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS | IRM LLC (BM) | 2012-08-23 | — | — | US | claimed |
| EP-2164849-A2 | PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF | AEterna Zentaris GmbH (DE) | 2010-03-24 | — | — | EP | claimed |
| US-20090325981-A1 | Compounds and compositions as lxr modulators | IRM LLC (BM) | 2009-12-31 | — | — | US | claimed |
| US-20090275534-A1 | NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF | ZENTARIS GMBH (DE) | 2009-11-05 | — | — | US | claimed |
| WO-2008138878-A2 | NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF | ÆTERNA ZENTARIS GMBH (DE) | 2008-11-20 | — | — | WO | claimed |
| EP-1990342-A1 | Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof | AEterna Zentaris GmbH (DE) | 2008-11-12 | — | — | EP | claimed |
| EP-1713799-A2 | COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS | IRM, LLC (BM) | 2006-10-25 | — | — | EP | claimed |
| WO-2005077124-A2 | COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS | IRM LLC (BM) | 2005-08-25 | — | — | WO | claimed |
| US-20130345220-A1 | COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS | IRM LLC (BM) | 2013-12-26 | — | — | US | disclosed |
| US-8604196-B2 | Modulating signal transduction pathways with 1-ethyl-3-[3-(1-methyl-1H-pyrazol-4-yl)-pyrido[2.3-B]pyrazine-6-yl]thiourea | AETERNA ZENTARIS GMBH (DE) | 2013-12-10 | — | — | US | disclosed |
| US-8569345-B2 | Compounds and compositions as LXR modulators | MOLTENI VALENTINA (US) | 2013-10-29 | — | — | US | disclosed |
| US-8536332-B2 | Modulating signal transduction pathways with substituted pyridol [2,3-b] pyrazines | AETERNA ZENTARIS GMBH (DE) | 2013-09-17 | — | — | US | disclosed |
| US-8507486-B2 | Pyridopyrazine derivatives, process of manufacturing and uses thereof | AETERNA ZENTARIS GMBH (DE) | 2013-08-13 | — | — | US | disclosed |
| US-20120277219-A1 | NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF | AETERNA ZENTARIS GMBH (DE) | 2012-11-01 | — | — | US | disclosed |
| US-20090325981-A1 | Compounds and compositions as lxr modulators | IRM LLC (BM) | 2009-12-31 | — | — | US | disclosed |
| US-20090275534-A1 | NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF | ZENTARIS GMBH (DE) | 2009-11-05 | — | — | US | disclosed |
| WO-2008138878-A2 | NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF | ÆTERNA ZENTARIS GMBH (DE) | 2008-11-20 | — | — | WO | disclosed |
| EP-1990342-A1 | Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof | AEterna Zentaris GmbH (DE) | 2008-11-12 | — | — | EP | disclosed |
| EP-1713799-A2 | COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS | IRM, LLC (BM) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005077124-A2 | COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS | IRM LLC (BM) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345220-A1 | COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS | NR1H2, NR1H3, NR1H4 | POLB 3374/4885ESR2 49/4885CA2 4724/4885 |
| US-20090275534-A1 | NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF | PNPO, PDXK, MKI67 | POLB 836/4885ESR2 4290/4885CA2 4352/4885 |
| US-20120277219-A1 | NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF | PNPO, PDXK, MKI67 | POLB 836/4885ESR2 4290/4885CA2 4352/4885 |
| US-20090325981-A1 | Compounds and compositions as lxr modulators | NR1H2, NR1H3, NR1H4 | POLB 3374/4885ESR2 49/4885CA2 4724/4885 |
| US-20120214812-A1 | COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS | NR1H2, NR1H3, NR1H4 | POLB 3374/4885ESR2 49/4885CA2 4724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.